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ABSTRACT 
Human Immunodeficiency Virus (HIV), the etiological agent of the Acquired Immune 
Deficiency Syndrome (AIDS) poses a worldwide threat to public health. The ability of HIV 
to adapt to current antiviral drug therapy places some importance on other means to inhibit 
viral replication. Ribozymes may offer a promising avenue of research in the battle against 
HIV. Hammerhead ribozymes are RNA molecules that act as enzymes, catalyzing the 
substrate-specific cleavage of target RNAs. Ribozyme targeting of HIV RNAs essential to 
replication have been shown to reduce or inhibit viral replication. Among the genes most 
commonly targeted are tat and rev, which regulate viral transcription and post-transcriptional 
modification, respectively. In this paper we describe the design, synthesis, and cloning of a 
hammerhead ribozyme targeted to HIV-1 v//(Virion Infectivity Factor). This gene encodes 
a protein that enhances viral infectivity by blocking a host antiviral defense pathway, which 
relies on the host protein APOBEC3G Vifs ability to inhibit this cellular defense mechanism 
makes it a potentially advantageous target for ribozyme-mediated down-regulation of HIV. 
INTRODUCTION 
The identification of the Human Immunodeficiency Virus as the causative agent of AIDS 
in 1983 was accompanied by a tremendous research effort directed at limiting or preventing 
the spread of this virus into susceptible populations. While these measures have temporarily 
succeeded in reducing the number of HIV infected individuals who progress to AIDS, they 
are not curative. To this end, the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
estimated in late 2003 that about 40 million people worldwide were infected with HIV, and 
in that year alone, approximately 5 million new HIV infections and 3 million AIDS-related 
deaths occurred (NIAID, 2004). 
The rapid adaptation of HIV-1 to antiviral drugs (Freeman and Herron, 2001) gives 
some urgency to investigating other means to inhibit viral replication. One such area of 
investigation involves the use of catalytic RNAs, or ribozymes, to target and cleave viral 
mRNAs. Ribozymes are RNA molecules that act as enzymes, catalyzing the substrate-specific 
cleavage of substrate RNAs (Cech, 1989). Ribozyme targeting of HIV mRNAs could 
potentially inhibit viral replication by reducing HIV gene expression and limiting assembly 
of viral progeny. One class of catalytic RNA was found to exist naturally in the satellite 
RNA of tobacco ringspot virus (sTobRV) (Prody et al., 1986). Forster and Symons (1987) 
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identified characteristic conserved sequences of the ribozyme and noted the secondary 
hammerhead-shaped structure. Haseloff and Gerlach (1988) defined the minimal ribozyme 
sequence necessary for cleavage and developed a model for ribozyme design. Cleavage of 
substrate RNAs by hammerhead ribozymes depends on the availability of target sites that 
were initially defined by Haseloff and Gerlach (1988) and later broadened by Perriman et al. 
(1992). These sites can be defined as any XUX', where X is any ribonucleotide and X' is an 
A, C, or U (Perriman et al., 1992). Ribozyme-mediated cleavage occurs immediately 3' of 
the X' nucleotide (Perriman et al, 1992). Several investigations have studied the use of 
hammerhead ribozymes to inhibit specific viral functions. Studies published by Zhou et al. 
(1994) and Jackson et al. (1998) confirmed the ability for hammerhead ribozymes to target 
HIV-1 RNA and inhibit subsequent replication. Favored HIV targets have been tat and rev, 
which encode regulatory proteins responsible for regulating transcription from the viral 
promoter and post-transcriptional splicing of transcripts, respectively. Other HIV targets 
may also prove to be valuable targets for viral inhibition. One such target is HIV-1 vif 
(Virion Infectivity Factor), which encodes a protein that neutralizes an inhibitory host defense 
mechanism mediated by apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 
3G (APOBEC3G) (Navarro and Landau, 2004). APOBEC3G is a cellular cytidine deaminase 
that is encapsulated into assembling virions in the absence of vif and is inhibitory during the 
next round of viral replication (Navarro and Landau, 2004). J^/neutralizes APOBEC3G by 
reducing its translation and by rapid degradation of the native protein (Navarro and Landau, 
2004). 
Vif?, ability to inhibit the host cell's retrovirus defense mechanism makes it a potentially 
advantageous target for ribozyme binding and associated decreased expression of HIV. This 
paper describes the design, synthesis, and cloning of a catalytic and noncatalytic (A) control 
hammerhead ribozyme targeted to HIV-1 vz/mRNA 
METHODS AND MATERIALS 
Ribozyme Design and Synthesis. The HIV-1 NL43 mRNA sequence (accession number 
M19921) was analyzed for potential ribozyme target sites (Perriman et al., 1992; Haseloff 
and Gerlach, 1988). One such target, a pGUU was located at nucleotide 5154. An anti-v// 
ribozyme, W5154, consisting of the hammerhead ribozyme catalytic core and 12-nucleotide 
complementary flanking regions was designed to this sequence (Figure 1). An identical 
non-catalytic control ribozyme, Vif5154A, was designed by changing the adenine located at 
position 21 in the catalytic core to a guanine (Zhou et al, 1994). Each ribozyme was converted 
to DNA and used to design forward and reverse primers for PCR. The two ribozyme DNA 
templates (5'-GTG ATG TCT ATA ACT GAT GAG TCC GTG AGG ACG (A/G)AA CCA 
GTC CTT AGC-3') and associated PCR primers (forward, 5'-GTG ATG TCT ATA ACT 
GAT GAG TC-3' and reverse, 5'-GCT AAG GAC TGG TT(T/C) CGT C-3') were synthesized 
(Integrated DNA Technologies, Inc., Coralville, IA) and used to generate dsDNA ribozymes. 
Amplification of Vif5154 and Vif5154A Riboyzmes. To generate dsDNA ribozymes 
suitable for cloning, the synthesized Vif5154 and Vif5154A ribozyme DNAs were used as 
templates for the polymerase chain reaction (PCR). Briefly, 200pMol ribozyme template, 
lOOOpMol of the appropriate forward and reverse primers were added to lx thermostable 
buffer, 4mM dNTPs, lOOmMol MgS04, and 2.5 units of Vent DNA polymerase (New England 
Biolabs, Beverly, MA). PCR was conducted under the following conditions: dissociation at 
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Figure 1. Design of anti-Vif ribozymes. Two hammerhead ribozymes targeted to a pGUU target in 
HIV-1 NL43 Vif mRNA were designed based on the Haseloff and Gerlach model (1988). Each 
ribozyme consisted of a catalytic core and complementary flanking regions (underlined) that 
provide substrate specificity. Catalytic activity was abolished by substituting a guanine at position 
21 in the catalytic core (Zhou, 1994). 
94°C for 30 seconds, primer annealing at 52.5°C (W5154) or 52.8°C (W5154A) for 30 
seconds, and extension at 72°C for 60 seconds. This process was repeated for 30 cycles. 
Amplified DNA was analyzed by gel electrophoresis for the presence of a 48 base pair 
fragment indicative of both ribozymes (data not shown). 
Ligation and Transformation of W5154 and Vif5154A Riboyzmes. Each amplified 
ribozyme was cloned into the shuttle vector pPCR-Script Amp Sk(+) (Stratagene, La Jolla, 
CA) by blunt-end ligation according to the manufacturer's recommendation. Briefly, each 
ligation reaction was carried out in 50ul using lOng pPCR-Script, 0.5mM rATP, 5U Srfl, 4U 
T4 DNAligase, 2ul PCR product, and lx reaction buffer. Ligation reactions were incubated 
at room temperature for 1 hour, followed immediately by transformation of XL 10 Gold 
Ultracompetent E.coli cells (Stratagene, La Jolla, CA). 
XL10 Gold cells were thawed on ice, and 40ul were aliquoted into sterile, prechilled 
17x150mm tubes along with 1.6ul of/?-mercaptoethanol. Two microliters of the respective 
ligation reaction were added to each tube, and the cells were incubated on ice for 30 minutes 
then heat-pulsed in a 42°C water bath for 30 seconds. The cells were removed from the bath 
and incubated on ice for two minutes. Four hundred microliters of preheated (42°C) SOC 
broth were added to each tube and the cells were incubated for 1 hour at 37°C and 225 rpm. 
Fifty microliters of cells were plated onto Luria-Bertani (LB)/Amp (50ug/ml) along with 
lOul of 50mg/ml X-gal and lOul of lOmM IPTG. Each plate was incubated overnight at 
37°C. Four white colonies from the Vif5154 plate and five white colonies from the Vif5154A 
plate were picked for analysis. Each colony was used to inoculate 2ml of LB/Amp (50[j,g/ 
ml) broth and incubated overnight at 37°C and 225 rpm. 
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Clone Analysis of Vif5154 and Vif5154A Riboyzmes. Plasmid DNA was extracted 
from transformed E. colt using a miniprep procedure (Sambrooketal., 1989). One milliliter 
of each cultures was centrifuged for 4 minutes, the medium was aspirated, and the pellets 
were resuspended in lOOul of ice cold Solution I (50mM glucose, 25mM Tris CI [pH 8.0], 
lOmM EDTA [pH 8.0]). Two hundred microliters of freshly prepared Solution II (ION 
NaOH [20ul], 10% SDS [lOul], 970ul dH20) were added and mixed by inversion. The 
lysates were placed on ice and 150ul of ice cold Solution III (5 M potassium acetate [60ml], 
glacial acetic acid [11.5ml], dH20 [28.5 ml]) were added and mixed by gentle inversion. 
The lysate was allowed to precipitate on ice for 5 minutes, and centrifuged for 5 minutes. 
The supernatant was transferred to a new microcentrifuge tube, and plasmid DNA was 
precipitated with 2 volumes of ethanol for 2 minutes. The supernatant was decanted after a 
10-minute centrifugation. Remaining pellets were washed with an additional volume of 
ethanol and the dried pellets were redissolved in 25ul of dH20. 
Presence and Orientation Analysis of Cloned Ribozymes. To determine ribozyme 
presence within plasmid DNA, PCR was conducted using M13 primers. Briefly, each reaction 
was carried out in 50ul using lOOpMol each of M13 forward and reverse primers, 2ul miniprep 
DNA, and 1.25U of 2x Taq (Takara, Madison, WI). PCR was carried out as described with 
annealing temperatures of either 55°C for potential catalytic ribozyme clones or 54°C for 
potential noncatalytic ribozyme clones. PCR fragments were analyzed by gel electrophoresis 
for the presence of a 274 base pair fragment indicative of both ribozymes. 
Orientation of the ribozymes with respect to the T7 promoter of pPCR-Script was 
determined by gel electrophoresis of PCR reactions using M13 primers, ribozyme primers, 
and Taq (Takara, Madison, WI). Each reaction was carried out in 50ul using lOOpMol of a 
premix containing Ml3 forward primer and either ribozyme forward or reverse primer, 2ul 
miniprep clone DNA, and 1.25U 2x Taq (Takara, Madison, WI). PCR was conducted as 
previously mentioned, with annealing temperatures of 54°C for pVif5154 clones and 55°C 
for pVif5154A clones. PCR fragments were analyzed by gel electrophoresis for the presence 
of a 176 base pair fragment for both ribozymes. Positive clones was sent to the Medical 
College of Georgia's Core Facilities for direct sequencing to confirm cloning (Medical College 
of Georgia, Augusta, Georgia). 
RESULTS 
Design and cloning of anti-vi/ ribozymes. ApGUU at nucleotide 5154 of HIV-1 vif 
mRNA was identified as a potential site for ribozyme cleavage (Perriman et al, 1992). A 
hammerhead ribozyme was designed to target this mRNA based on the model of Haseloff 
and Gerlach (1988). Additionally, a control, non-catalytic ribozyme was designed by 
substituting a guanine for an adenine residue at position 21 of the catalytic core (Zhou et al, 
1994). Each ribozyme sequence was converted to DNA and used to design forward and 
reverse primers for PCR. The Vif5154 catalytic and Vif5154A noncatalytic ribozyme DNAs 
were synthesized along with the appropriate PCR primers. Each ribozyme DNA was amplified 
and visualized by gel electrophoresis prior to cloning into pPCR-Script. Gel analyses revealed 
PCR fragments of approximately 48bp for both Vif5154 and Vif5154A ribozymes (data not 
shown), indicating successful ribozyme amplification. Amplified ribozymes were cloned 





Figure 2. Analysis of ribozyme presence and orientation. Plasmid DNAs were screened for 
ribozyme presence and orientation by PCR using plasmid- and ribozyme-specific primers. 
Presence was confirmed by the amplification of a 274bp fragment: panel A, lanes 1-3 for W5154 
and panel C, lanes 1,4, and 7 for W5154A ribozymes. Orientation was determined by the 
amplification of a 176bp fragment in one of two paired reactions using a plasmid-specific primer 
in combination with each ribozyme-specific primer. The presence of a 176bp fragment in panel B, 
lane 1 along with the absence of a band in lane 2 indicated Vif5154 ribozyme orientation inverted 
with respect to the plasmid T7 promoter. Similar results were observed in panel C, lane 2 which 
along with the absence of a band in lane 3 indicated W5154A ribozyme orientation was also 
inverted. The remaining reactions gave no clear indication of orientation and were discarded. All 
agrose gels were run in 1XTAE. 
Analysis of ribozyme presence and orientation. Miniprep DNA was analyzed for 
ribozyme presence and orientation by PCR using plasmid-specific and ribozyme-specific 
primers. Three of four clones analyzed for Vif5154 ribozyme resulted in amplification of a 
274bp fragment (Figure 2A) as determined using the plasmid map. In addition, three of five 
clones analyzed for Vif5154A ribozyme resulted in amplification of a 274bp fragment (Figure 
2C). Each of these six clones was further analyzed by PCR for ribozyme orientation with 
respect to the pPCR-Script T7 promoter. Two reactions were carried out for each clone 
using a combination of M13 forward/ribozyme forward or M13 forward/ribozyme reverse 
primers, each of which could result in a 176bp fragment. However, in this analysis successful 
PCR is solely determined by the ribozyme orientation such that only one positive reaction 
should occur for any clone. The orientation analysis clearly revealed that one Vif5154 
ribozyme clone and one Vif5154A ribozyme clone contained the cloned sequences in an 
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orientation inverted with respect to the T7 promoter (Figure 2B and 2C). These clones were 
subsequently sent for direct sequencing (Medical College of Georgia Genomics Core Facility, 
Augusta, GA). Sequencing results for Vif5154: GCT AAG GAC TGG TTT CGT CCT CAC 
GGA CTC ATC AGT TAT AGA CAT CAC; and W5154A: GCT AA G GAC TGG TTC 
CGT CCT CAC GGA CTC ATC AG T TAT AGA CAT CAC verified that each was inverted 
with respect to the T7 promoter. 
DISCUSSION 
Hammerhead ribozymes are catalytic RNA molecules that cleave in a substrate-specific 
manner (Forster and Symons, 1987). Targeting of HIV mRNAs by ribozymes could 
potentially inhibit viral replication by reducing HIV gene expression and limiting viral progeny 
assembly (Zhou, 1994, Jackson et al, 1998). Although tat and rev have been favored HIV 
targets due to their functions of transcription regulation and post-transcriptional splicing, 
vif's ability to inhibit the host cell's retrovirus defense mechanism also makes it a potentially 
advantageous target for ribozyme binding and associated decreased expression of HIV. 
To test this hypothesis, a pGUU cleavage site at nucleotide 5154 of HIV-1 NL43 Vif 
mRNA was identified and a catalytic hammerhead ribozyme was designed. Anon-catalytic 
control ribozyme was also designed by substituting a guanine for the adenine residue at 
position 21 of the catalytic core (Zhou et al, 1994). Each ribozyme was cloned into the 
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Figure 3. Plasmid maps of anit-w/ribozymes. Direct sequencing results were used to design plasmid 
maps showing the pPCR-Script Amp SK(+) shuttle vector containing cloned robozymes, pVif5154 
robozyme (A.) and pVif5154A ribozyme (B.). Each ribozyme is cloned into the Multiple Cloning 
Site (MCS) of the pPCR-Script, and is inverted with respect to the T7 promoter. 
plasmids, pVif5154Rz and pVif5154ARz (Figure 3) complement two previously cloned 
ribozymes that target HIV-1 vz/mRNA at nucleotides 5113 and 5127. The cleavage activity 
of these anti-vz/ ribozymes will be determined in an in vitro cleavage assay. Individual 
ribozyme kinetics will be calculated and used to determine those ribozymes best suited for 
further testing in tissue culture models of HIV-1 replication. 
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